1
|
Zhang Y, Liu W, Fu C, Liu X, Hou X, Niu H, Li T, Guo C, Li A, Chen B, Jin X. Diabetes and vascular mild cognitive impairment among Chinese ≥50 years: A cross-sectional study with 2020 participants. Brain Behav 2024; 14:e3477. [PMID: 38680021 PMCID: PMC11056693 DOI: 10.1002/brb3.3477] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/17/2022] [Revised: 02/15/2024] [Accepted: 03/07/2024] [Indexed: 05/01/2024] Open
Abstract
BACKGROUND With the decline of cognitive function in vascular cognitive impairment, the burden on the family and society will increase. Therefore, early identification of vascular mild cognitive impairment (VaMCI) is crucial. The focus of early identification of VaMCI is on the attention of risk factors. Therefore, this study aimed to investigate the relationship between diabetes and VaMCI among the Chinese, hoping to predict the risk of VaMCI by diabetes and to move the identification of vascular cognitive impairment forward. METHODS We collected data from seven clinical centers and nine communities in China. All participants were over 50 years of age and had cognitive complaints. We collected basic information of the participants, and cognitive function was professionally assessed by the Montreal Cognitive Assessment scale. Finally, logistic regression analysis was used to analyze the correlation between each factor and VaMCI. RESULTS A total of 2020 participants were included, including 1140 participants with VaMCI and 880 participants with normal cognition. In univariate logistic regression analysis, age, heavy smoking, and diabetes had a positive correlation with VaMCI. At the same time, being married, high education, and light smoking had a negative correlation with VaMCI. After correction, only diabetes (OR = 1.04, 95% CI: 1.01-1.09, p = 0.05) had a positive correlation with VaMCI, and high education (OR = 0.60, 95% CI:.45-.81, p = 0.001) had a negative correlation with VaMCI. CONCLUSION In our study, we found that diabetes had a positive correlation with VaMCI, and high education had a negative correlation with VaMCI. Therefore, early identification and timely intervention of diabetes may reduce the risk of VaMCI and achieve early prevention of VaMCI.
Collapse
Affiliation(s)
- Yu Zhang
- Department of NeurologyDongfang HospitalBeijing University of Chinese MedicineBeijingChina
| | - Wenna Liu
- Clinical Trial InstitutionDongfang HospitalBeijing University of Chinese MedicineBeijingChina
| | - Chen Fu
- Central LaboratoryDongfang HospitalBeijing University of Chinese MedicineBeijingChina
| | - Xuemei Liu
- Central LaboratoryDongfang HospitalBeijing University of Chinese MedicineBeijingChina
| | - Xiaobing Hou
- Department of NeurologyBeijing First Hospital of Integrated Chinese and Western MedicineBeijingChina
| | - Huanmin Niu
- Department of NeurologyBeijing First Hospital of Integrated Chinese and Western MedicineBeijingChina
| | - Tao Li
- Department of GerontologyShanxi Traditional Chinese Medicinal HospitalTaiyuanChina
| | - Chunyan Guo
- Department of NeurologyDongfang HospitalBeijing University of Chinese MedicineBeijingChina
| | - Aixun Li
- Department of NeurologyDongfang HospitalBeijing University of Chinese MedicineBeijingChina
| | - Baoxin Chen
- Department of NeurologyDongfang HospitalBeijing University of Chinese MedicineBeijingChina
| | - Xianglan Jin
- Department of NeurologyDongfang HospitalBeijing University of Chinese MedicineBeijingChina
| |
Collapse
|
2
|
Yekeler HB, Guler E, Beato PS, Priya S, Abobakr FKM, Dogan M, Uner B, Kalaskar DM, Cam ME. Design and in vitro evaluation of curcumin-loaded PLGA nanoparticle-embedded sodium alginate/gelatin 3D printed scaffolds for Alzheimer's disease. Int J Biol Macromol 2024; 268:131841. [PMID: 38679260 DOI: 10.1016/j.ijbiomac.2024.131841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2024] [Revised: 04/18/2024] [Accepted: 04/23/2024] [Indexed: 05/01/2024]
Abstract
BACKGROUND Targeted nanoparticles (NPs) are aimed at improving clinical outcomes by enhancing the diagnostic and therapeutic efficacy of drugs in the treatment of Alzheimer's disease (AD). METHODS Curcumin (CUR)-loaded poly-lactic-co-glycolic acid (PLGA) NPs (CNPs) were produced to demonstrate a prolonged release and successfully embedded into 3D printed sodium alginate (SA)/gelatin (GEL) scaffolds that can dissolve rapidly sublingually. Characterization and in vitro activity of the NPs and scaffolds were evaluated. RESULTS Based on the in vitro drug release studies, 99.6 % of the encapsulated CUR was released in a controlled manner within 18 days for the CNPs. In vitro cell culture studies showed that all samples exhibited cell viability above 84.2 % and no significant cytotoxic effect on SH-SY5Y cells. The samples were analyzed through 2 different pathways by PCR analysis. Real-time PCR results indicated that CNP and CNP-embedded SA/GEL scaffolds (CNPSGS) may show neuroprotective effects by modulating the Wnt/β-catenin pathway. The gene expression level of β-catenin slightly increased compared to the gene expression levels of other proteins and enzymes with these treatments. However, the PI3K/Akt/GSK-3β signaling pathway was regulated at the same time because of the crosstalk between these 2 pathways. CONCLUSION CNPSGS might be an effective therapeutic alternative for AD treatment.
Collapse
Affiliation(s)
- Humeyra Betul Yekeler
- Department of Pharmacology, Faculty of Pharmacy, Marmara University, Istanbul 34854, Türkiye; Center for Nanotechnology and Biomaterials Application and Research, Marmara University, Istanbul 34722, Türkiye; UCL Division of Surgery and Interventional Science, Royal Free Hospital Campus, University College London, Rowland Hill Street, NW3 2PF, UK; MecNano Technologies, Cube Incibation, Teknopark Istanbul, Istanbul 34906, Türkiye
| | - Ece Guler
- Center for Nanotechnology and Biomaterials Application and Research, Marmara University, Istanbul 34722, Türkiye; UCL Division of Surgery and Interventional Science, Royal Free Hospital Campus, University College London, Rowland Hill Street, NW3 2PF, UK; MecNano Technologies, Cube Incibation, Teknopark Istanbul, Istanbul 34906, Türkiye; Department of Pharmacology, Faculty of Pharmacy, Istanbul Kent University, Kagithane 34406, Istanbul, Türkiye
| | - Patricia Santos Beato
- UCL Division of Surgery and Interventional Science, Royal Free Hospital Campus, University College London, Rowland Hill Street, NW3 2PF, UK
| | - Sushma Priya
- UCL Division of Surgery and Interventional Science, Royal Free Hospital Campus, University College London, Rowland Hill Street, NW3 2PF, UK
| | | | - Murat Dogan
- Department of Pharmaceutical Biotechnology, Cumhuriyet University, Sivas 58140, Türkiye; Cancer Survivorship Institute, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, 625 N. Michigan Ave., Suite 2100, Chicago, IL, 60611, USA
| | - Burcu Uner
- Department of Pharmaceutical and Administrative Sciences, University of Health Science and Pharmacy in St. Louis, St. Louis, MO, USA; Department of Pharmaceutical Technology, Faculty of Pharmacy, Istanbul Kent University, Kagithane 34406, Istanbul, Türkiye
| | - Deepak M Kalaskar
- UCL Division of Surgery and Interventional Science, Royal Free Hospital Campus, University College London, Rowland Hill Street, NW3 2PF, UK
| | - Muhammet Emin Cam
- Center for Nanotechnology and Biomaterials Application and Research, Marmara University, Istanbul 34722, Türkiye; UCL Division of Surgery and Interventional Science, Royal Free Hospital Campus, University College London, Rowland Hill Street, NW3 2PF, UK; MecNano Technologies, Cube Incibation, Teknopark Istanbul, Istanbul 34906, Türkiye; Department of Pharmacology, Faculty of Pharmacy, Istanbul Kent University, Kagithane 34406, Istanbul, Türkiye; Biomedical Engineering Department, University of Aveiro, Aveiro 3810-193, Portugal; Genetic and Metabolic Diseases Research and Investigation Center, Marmara University, Istanbul 34854, Türkiye.
| |
Collapse
|
3
|
Polat EB, Hazar-Yavuz AN, Guler E, Ozcan GS, Taskin T, Duruksu G, Elcioglu HK, Yazır Y, Cam ME. Sublingual Administration of Teucrium Polium-Loaded Nanofibers with Ultra-Fast Release in the Treatment of Diabetes Mellitus: In Vitro and In Vivo Evaluation. J Pharm Sci 2024; 113:1068-1087. [PMID: 38123068 DOI: 10.1016/j.xphs.2023.12.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Revised: 12/14/2023] [Accepted: 12/14/2023] [Indexed: 12/23/2023]
Abstract
In this study, Teucrium polium (TP) methanolic extract, which has antidiabetic activity and protects the β-cells of the pancreas, was loaded in polyethylene oxide/sodium alginate nanofibers by electrospinning and administered sublingually to evaluate their effectiveness in type-2 diabetes mellitus (T2DM) by cell culture and in vivo studies. The gene expressions of insulin, glucokinase, GLUT-1, and GLUT-2 improved in TP-loaded nanofibers (TPF) on human beta cells 1.1B4 and rat beta cells BRIN-BD11. Fast-dissolving (<120 s) sublingual TPF exhibited better sustainable anti-diabetic activity than the suspension form, even in the twenty times lower dosage in streptozotocin/nicotinamide-induced T2DM rats. The levels of GLP-1, GLUT-2, SGLT-2, PPAR-γ, insulin, and tumor necrosis factor-alpha were improved. TP and TPF treatments ameliorated morphological changes in the liver, pancreas, and kidney. The fiber diameter increased, tensile strength decreased, and the working temperature range enlarged by loading TP in fibers. Thus, TPF has proven to be a novel supportive treatment approach for T2DM with the features of being non-toxic, easy to use, and effective.
Collapse
Affiliation(s)
- Elif Beyzanur Polat
- Department of Pharmacology, Faculty of Pharmacy, Marmara University, Istanbul 34854, Turkiye
| | - Ayse Nur Hazar-Yavuz
- Department of Pharmacology, Faculty of Pharmacy, Marmara University, Istanbul 34854, Turkiye
| | - Ece Guler
- Department of Pharmacology, Faculty of Pharmacy, Marmara University, Istanbul 34854, Turkiye; Department of Pharmacology, Faculty of Pharmacy, Istanbul Kent University, Istanbul 34406, Türkiye; Center for Nanotechnology and Biomaterials Application and Research, Marmara University, Istanbul 34722, Turkiye; MecNano Technologies, Cube Incibation, Teknopark Istanbul, Istanbul 34906, Türkiye
| | - Gul Sinemcan Ozcan
- MecNano Technologies, Cube Incibation, Teknopark Istanbul, Istanbul 34906, Türkiye; Stem Cell and Gene Therapies Research and Applied Center, Medical Faculty, Kocaeli University, Kocaeli 41380, Turkiye
| | - Turgut Taskin
- Department of Pharmacognosy, Faculty of Pharmacy, Marmara University, Istanbul 34854, Turkiye
| | - Gokhan Duruksu
- Genetic and Metabolic Diseases Research and Investigation Center, Marmara University, Istanbul 34722, Turkiye
| | - Hatice Kubra Elcioglu
- Department of Pharmacology, Faculty of Pharmacy, Marmara University, Istanbul 34854, Turkiye
| | - Yusufhan Yazır
- Stem Cell and Gene Therapies Research and Applied Center, Medical Faculty, Kocaeli University, Kocaeli 41380, Turkiye
| | - Muhammet Emin Cam
- Department of Pharmacology, Faculty of Pharmacy, Marmara University, Istanbul 34854, Turkiye; Department of Pharmacology, Faculty of Pharmacy, Istanbul Kent University, Istanbul 34406, Türkiye; Center for Nanotechnology and Biomaterials Application and Research, Marmara University, Istanbul 34722, Turkiye; MecNano Technologies, Cube Incibation, Teknopark Istanbul, Istanbul 34906, Türkiye; Genetic and Metabolic Diseases Research and Investigation Center, Marmara University, Istanbul 34722, Turkiye; Biomedical Engineering Department, University of Aveiro, Aveiro 3810-193, Portugal; SFA R&D Laboratories, Teknopark Istanbul, Istanbul 34906, Türkiye; ATA BIO Technology, Teknopol Istanbul, Istanbul 34930, Türkiye.
| |
Collapse
|
4
|
Li Z, Zhang Z, Zhang Z, Wang Z, Li H. Cognitive impairment after long COVID-19: current evidence and perspectives. Front Neurol 2023; 14:1239182. [PMID: 37583958 PMCID: PMC10423939 DOI: 10.3389/fneur.2023.1239182] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2023] [Accepted: 07/12/2023] [Indexed: 08/17/2023] Open
Abstract
COVID-19, caused by the SARS-CoV-2 virus, is a respiratory infectious disease. While most patients recover after treatment, there is growing evidence that COVID-19 may result in cognitive impairment. Recent studies reveal that some individuals experience cognitive deficits, such as diminished memory and attention, as well as sleep disturbances, suggesting that COVID-19 could have long-term effects on cognitive function. Research indicates that COVID-19 may contribute to cognitive decline by damaging crucial brain regions, including the hippocampus and anterior cingulate cortex. Additionally, studies have identified active neuroinflammation, mitochondrial dysfunction, and microglial activation in COVID-19 patients, implying that these factors may be potential mechanisms leading to cognitive impairment. Given these findings, the possibility of cognitive impairment following COVID-19 treatment warrants careful consideration. Large-scale follow-up studies are needed to investigate the impact of COVID-19 on cognitive function and offer evidence to support clinical treatment and rehabilitation practices. In-depth neuropathological and biological studies can elucidate precise mechanisms and provide a theoretical basis for prevention, treatment, and intervention research. Considering the risks of the long-term effects of COVID-19 and the possibility of reinfection, it is imperative to integrate basic and clinical research data to optimize the preservation of patients' cognitive function and quality of life. This integration will also offer valuable insights for responding to similar public health events in the future. This perspective article synthesizes clinical and basic evidence of cognitive impairment following COVID-19, discussing potential mechanisms and outlining future research directions.
Collapse
Affiliation(s)
- Zhitao Li
- Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing, China
- The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China
| | - Zhen Zhang
- Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China
| | - Zhuoya Zhang
- Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China
| | - Zhiyong Wang
- Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China
| | - Hao Li
- Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing, China
| |
Collapse
|